ARTV

#2861
Artiva Biotherapeutics, Inc. - Common Stock
11.3 0 USD
+0.02%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
11.30
11.30
Intervallo Annuale
4.07
14.53
Variazione giornaliera
+1.89%
Variazione Mensile
+13.00%
Variazione di 6 mesi
+106.58%
Variazione Annuale
+171.63%
Chiusura Precedente
11.0 9
Open
11.3 0
Minimo
11.3 0
Massimo
11.3 0
Volume
58
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Artiva Biotherapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Artiva Biotherapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Artiva Biotherapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Artiva Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Artiva Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Artiva Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Artiva Biotherapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Artiva Biotherapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Artiva Biotherapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Artiva Biotherapeutics, Inc. current report, Q1 FY2026
8-K

Artiva Biotherapeutics, Inc. current report, Q2 FY2025

Full document

Business Context and Reporting Period

This Form 8-K Current Report from Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) covers events occurring on June 24, 2025, specifically the Company's 2025 Annual Meeting of Stockholders. The filing details the outcomes of shareholder votes and corporate governance actions taken during the meeting.

Key Financial Metrics

This filing is a current report regarding corporate governance and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes and Voting Results

As of the record date (April 25, 2025), 24,363,119 shares of common stock were outstanding and entitled to vote. The following proposals were approved or ratified:

  • Election of Class I Director: Daniel Baker, Ph.D., was elected to a three-year term. He received 18,913,133 votes for, with 22,995 votes withheld and 1,838,803 broker non-votes.
  • Ratification of Auditors: Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The vote was 20,772,359 for, 300 against, and 2,272 abstentions.
  • Equity Plan Amendment: Stockholders approved an amendment to the 2024 Equity Incentive Plan to increase the number of authorized shares by 1,214,580. The vote was 16,350,669 for, 2,583,159 against, and 2,300 abstentions.

Guidance, Outlook, and Risks

The filing does not contain management commentary on future guidance, outlook, or specific risk factors. The primary focus is the administrative approval of the amended equity plan and the election of directors. The 2024 Amended Plan is filed as Exhibit 10.1 to this report.

Investor Verification Checklist

  • Verify the total number of shares authorized under the amended 2024 Equity Incentive Plan by reviewing Exhibit 10.1.
  • Confirm the term end date for the newly elected director, Daniel Baker, Ph.D., which extends through the 2028 annual meeting.
  • Review the definitive proxy statement (Schedule 14A) filed on April 29, 2025, for detailed terms of the equity plan amendment.
  • Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial health metrics.